Anthracycline antibiotics are among the most effective and commonly used anticancer drugs.
Introduction
Doxorubicin (Dox) is one of the most potent broad-spectrum antitumor anthracycline antibiotics, widely used to treat a variety of cancers, including severe leukemias, lymphomas, and solid tumors (1), in combination with different drugs (Table I) . On the other hand, the clinical use of Dox is restricted because of its serious toxicity, which frequently leads to irreversible degenerative cardiomyopathy and heart failure (2) (3) (4) . The cytotoxic effect of Dox on malignant cells and its toxic effects on various organs (heart, liver, lung, kidney, blood cells, and testis) are thought to be related to the nucleotide base intercalation and the cell membrane lipid-binding activities of Dox (5) (6) (7) . Despite that, the precise mechanisms have not been fully established, and optimal therapeutic approaches for organo-protection remain undefined (8).
During the past decade, considerable progress has been made in investigating a protective role against doxorubicin-induced toxicity. There are many different approaches, agents and designs that have been tested for protecting in vivo-in vitro cells treated with Dox (9-15).
Doxorubicin-induced Toxicity
In 1976, a new ATP-requiring enzyme, DNA gyrase, was discovered in bacterial cells. It has the property of being able to change the topology of closed circular duplex DNA. DNA gyrase was found to have a crucial role in DNA replication, and for being able to pass one strand of DNA through another. It elegantly Technology in Cancer Research & Treatment, Volume 7, Number 6, December 2008 solved the problems of how DNA could be rapidly unwound during replication and how the daughter DNA strands could be separated after replication. Two main classes of enzymes were found in subsequent studies of mammalian cells. The first enzyme (topoisomerase I) changed DNA topology by breaking and rejoining a single DNA strand, while the second (topoisomerase II), with some of the characteristics of bacterial gyrase, broke both strands of one double-stranded DNA to allow passage of a second double-helical strand through the breakage point. The findings of the DNA topoisomerases also explained a problem regarding the activity of a number of natural products with anticancer activity that caused DNA damage but were not shown to respond chemically. Two anthracycline derivatives, daunorubicin and Dox, were found to bind DNA by intercalation of their chromophores. The clinical activity of daunorubicin was generally confined to hematologic malignancies, but that of Dox was broader. Dox was found to induce covalent links between DNA and proteins, and subsequent work established that this protein was in fact the enzyme topoisomerase II. The drugs acted as poisons for this enzyme, subverting its normal purpose to one of inducing DNA damage (16).
Dox reacts with cellular constituents in various ways. Its planar aglycone moiety can insert itself between adjacent DNA base pairs. Dox causes breaks in single-or double-stranded DNA. It modifies the ability of nuclear helicases to dissociate duplex DNA into single DNA strands. Dox, as well as others anthracyclines, can undergo one-and two-electron reduction, being members of the quinone family, and so produce reactive compounds that damage macromolecules and lipid membranes. After all, Dox destroys topoisomerase II in a way similar to etoposide (Figure 1 ). Complex signaling pathways are involved in activate apoptotic cell death by Dox. I kappa B alpha degradation and nuclear factor kappa B activation are early actions triggered by anthracyclines. Cathepsin B is expressed via NF-kappa B. The FAS/FASligand system and p53 are additional pathways used for Dox apoptosis in different cell lines. The presence of p21 (waf1/ cip1/sdi1), a cyclin-dependent kinase inhibitor, suppresses Dox, inducing apoptosis. Dox decreases sumoylation of KAP1 (transcriptional cofactor KRAB domain-associated protein 1) which induces p21 expression (1, 17) . preventive approaches are currently under demanding investigations. The mechanism primarily responsible for the cardiotoxic effects of anthracyclines is commonly accepted to be the generation of free radicals, involving iron-doxorubicin complexes that damage cardiac cellular membranes. Free radicals improve endothelial nitric oxide synthase production, which causes apoptosis in myocytes. Iron chelating agents can partly reduce Dox cardiotoxicity, but cannot completely protect cells from Dox cytotoxicity (19, 20) .
The percentage of adult patients with Dox-connected congestive heart failure is 5% at a cumulative dose of 400 mg/m 2 , increasing to 16% at a dose of 500 mg/m 2 , and 48% at a dose of 700 mg/m 2 . In a pediatric population, a 2.8% incidence of congestive heart failure has been reported during the 6 years following the administration of a mean cumulative dose of 300 mg/m 2 of Dox (1, 17, 21) .
It was found that older males, receiving higher doses of Dox, as well as radiotherapy, suffering from confirmed obesity, have a much greater chance of cardiac toxicity. The associated use of other drugs such as trastuzumab and paclitaxel raise the risk of Dox cardiotoxicity. Paclitaxel and docetaxel, at low concentrations, excite formation of the toxic metabolite doxorubicinol, which may be the cause of increased cardiotoxicity (17, 21) .
After administration, Dox is metabolized in the liver. Some effects, such as increase in plasma ALT, AST, and bilirubin levels, focal infiltration of inflammatory cells and steatosis in liver biopsies, have been found shortly after Dox administration. Focal injures in hepatocytes, steatosis, vascular damage, and ductules spuriae around central veins and in portocholangial spaces, may appear. Accordingly, subcellular hepatic alternations, counting polymorphic mitochondria, cytoplasmic vacuolization, and lipid droplet accumulation, were seen in Dox-induced hepatotoxicity. The glutathione-associated antioxidant ability of liver tissue may avoid free radical associated injury (5).
Pulmonary toxicity of Dox has been found but the mechanism is not yet established. It can cause a range of pulmonary toxicities such as bronchospasm, local edema, interstitial pneumonitis, and pulmonary fibrosis (7, 22, 23) .
Dox also has a nephrotoxic activity and produces chronic progressive glomerular disease. In rats with Dox-induced nephropathy, heavy proteinuria, associated with swelling and vacuolation of epithelial cells, have been presented in short-term tests. Dox-induced nephrosis provides a wellcharacterized model of progressive renal damage, induced by a uniform challenge at a single point in time. This results in proteinuria and subsequent structural renal damage with a relatively large variability between individuals. Severe re-nal damage, extensive glomerular lesions, tubular dilatation, vacuolization of renal glomeruli, protein deposits in tubular lumen and stromal fibrosis has been observed in long-term investigations. These experiments indicated that Dox-induced nephropathy is chronic and continually self-perpetuating, leading to terminal renal failure (1, 24).
As can be seen according to the reported results for Doxinduced toxicity, almost all organs can be attacked and damaged via the formation of free oxygen radicals and some of the organo-specific pathways.
Different Agents and Approaches for Protection Against Doxorubicin-induced Toxicity

Natural Products
Because of the great importance of Dox in cancer therapy, researchers have expended great efforts trying to prevent or attenuate the side effects of Dox administration. Accordingly, several approaches have been pursued in the 90's, such as dosage optimization, synthesis, and use of analogues or combined therapy. No hopeful results have been found and the application of different Dox-analogues did not show better antineoplastic value or lower toxicity than Dox.
The production of free radicals as a by product of Dox metabolism is considered to be the primary mechanism of Doxinduced toxicity, which suggests some new approaches, such as the potential use of natural antioxidants (13). The most commonly used and investigated compounds are vitamins (E, C, A, carotenoids), coenzyme Q, flavonoids, polyphenols, herbal antioxidants, selenium, and virgin olive oil (13). Some of the recently published papers concerning the use of natural products for protection against Dox-induced toxicity are listed in Table II .
Withania somnifera (WS) is an annual herb that is mostly known as ashwagandha. It has been used extensively as a valuable drug in Ayurveda. Withanolides are the major active compounds that are isolated from its root and leaves. According to the known anti-inflammatory, antitumor, antistress, antioxidant, immunomodulatory, and hepatoprotective effects of ashwagandha, Hamza et al. (29) investigated the potential cardioprotective influence of the herb extract in Dox-induced cardiomyopathy. The extract was used at a dose of 300 mg/kg/day p.o. (4.5 mg of withanolides) for two weeks. After the first seven days, the Dox and Dox/ WS groups received a single i.p. dose of Dox (10 mg/kg). At the end of the treatments, blood and heart tissues were collected and histological, immunohistochemical, and biochemical analyses were performed. They established that WS treatment, before and after Dox administration, ameliorated oxidative damage, and protected against cardiotoxicity induced by Dox in rats. The protective effect of WS may be mediated through its antioxidant, anti-inflammatory, and calcium-antagonistic properties. On the other hand, chronic supplementation with creatine and vitamins C and E increases survival and improves biochemical parameters after Dox treatment in rats, but not as successfully as WS (30). After one month of supplementing the rats with either creatine or vitamins, a single dose of Dox (15 mg/kg, i.p.) was administered. Dox treatment resulted in a significant increase in ALT, LDH, urea, and creatinine as compared to the control group. Creatine supplementation promoted a partial return to control values for LDH and creatinine, while the vitamin mix significantly reversed the changes in ALT, LDH, area, and creatinine. The final results of the study definitely show that a protective effect was more noticeable in animals that were treated with the mixture of vitamins C and E, than those treated with creatine. In further experiments Gokcimen et al. (32) tested N-acetylcysteine, caffeic acid, and vitamin E as potential hepatoprotectors. Unfortunately, once again only vitamin E, as a hydrophobic molecule, was found to be efficient against Dox-induced liver damage.
Centella asiatica (CA) is found almost all over the world and is also used in traditional Indian medicine for the management of the central nervous system, skin, and gastrointestinal disorders. The biological influence of CA includes anti-ulcer, anticancer, anti-inflammatory, and wound healing effects. It has a high antioxidant activity that is attributed to the presence of phenolic compounds (3-12 g/100 g dry sample), as well as an ACE-inhibitor activity. Therefore, Gnanapragasam et al. (33) investigated the protective role of CA in Dox-induced myocardial failure in rats. The goal of the study was to estimate the efficacy of CA on the mitochondrial enzymes, the mitochondrial antioxidant status in Dox-induced myocardial injury. After an i.p. administration of a single dose of 2.5 mg/kg, Dox induced mitochondrial damage in rats, which was assessed in terms of the decreased activities (p < 0.05) of cardiac marker enzymes (LDH, CPK, GOT, GPT), mitochondrial enzymes, respiratory marker enzymes, mitochondrial antioxidant enzymes (GSH-Px, GSH, SOD, CAT), and an increased (p < 0.05) level of lipid peroxidation. Mitochondrial damage was confirmed by transmission electron microscopic examination and pre-co-treatment with an aqueous extract of CA (200 mg/kg, p.o.), which not only possesses antioxidant properties but may also reduce the extent of mitochondrial damage.
Melatonin has been found to be effective in protecting organs against oxidative damage. For that purpose Oz et al. (34) used a protocol to define the degree of kidney, lung, liver, and brain cell changes after Dox treatment alone or in combination with melatonin. Rats were given Dox (45 mg/kg, i.v.) as a single dose, and melatonin (10 mg/kg/day, s.c.) for seven days before and after the application of Dox. A significant increase in lipid peroxidation products was observed in investigated organs after a single administration of Dox, which was attenuated by melatonin post-treatment.
Lycopene, a carotenoid naturally present in tomatoes, has received extensive interest for its role as an antioxidant. Concerning different defense strategies, lycopene is most likely involved in the scavenging of two of the reactive oxygen species, single molecular oxygen, and peroxyl radicals. While lycopene has been shown to offer some protection against Dox-induced cardiomyopathy, its effect on Dox-induced cardiac DNA damage is not known (36, 50, 51) .
Recently, two very similar investigations using the same protocols and group of authors (50, 51), confirmed a positive cardioprotective influence of a tomato-oleoresin supplement (lycopene) in Dox-induced toxicity. A very complex and long-term application of lycopene and/or Dox for 7 weeks was presented and the results confirmed lycopene absorption (after p.o. administration) via its cardiac levels, as well as Dox-induced oxidative DNA damage in the cardiomyocytes, and tomato-oleoresin supplementation was shown to protect against cardiomyocyte oxidative DNA damage (51).
Propolis, also called bee glue (Apis mellifera L.), as a water extract, was used in the examination of potential protection against Dox-induced somatic mutation and recombination in Drosophila melanogaster and against mitochondrial stress, induced by antineoplastic agents (Dox and vinblastin) in rats (43, 44) . Larvae (43) were chronically treated with different concentrations of the water extract of propolis alone or in combination with Dox (Table II) . Propolis was not shown to be toxic or genotoxic in Drosophila melanogaster somatic cells. Moreover, simultaneous treatment with different concentrations of propolis in water and Dox showed an inhibitory action against the incidence of mutant spots, induced by Dox, due to the anti-recombinogenic activity of propolis. The protective effects were comparative to the concentration applied, representing a dose-response correlation. On the other hand, in vivo investigation (44) strongly suggests that the propolis extract, administered 4 days prior to Dox (20 mg/kg) in a dose of 100 mg/kg/day (p.o.), protects the heart and liver tissues from oxidative stress by protecting the mitochondria. mice from Dox-induced cardiotoxicity as is evidenced by the enhanced ventricular contractile function, lower levels of serum LDH, CK, and CK-MB, minimal morphological changes in the hearts, and the normalization of myocardial SOD, GSH-Px, and CAT levels.
Despite extensive research, the mechanism of Dox-induced toxicity is still not completely elucidated and neither are the mechanisms of the different natural products acting as potential protectors. Furthermore, some other approaches have been established and they are presented in next paragraphs of this review paper.
Drugs
The discovery of drugs and the pharmaceutical industry are very dynamic and active, and there modern pharmacotherapy plays a significant role, and that is the reason reviews on this topic are usually necessary to keep up with new developments. Some well-known as well as new and potential drugs have been shown to have a significant influence on Dox-induced toxicity throughout different pathways of protection. The newly investigated approaches for using different drugs with Dox therapy are presented in Table III .
Amifostine is an analogue of cysteamine and, as a pro-drug, is dephosphorylated by membrane-bound alkaline phosphatases to its active metabolite, the free thiol. Its concentration is very high in healthy tissues and this selective uptake of amifostine is due to the high activity of membrane phosphatases in normal cells as compared to caner cells. Accordingly, the drug can protect the cells from radio-or chemotherapy induced side effects (63). Stolarska et al. (63) investigated the cytoprotective effect of amifostine in the treatment of childhood neoplastic diseases. The amifostine was first used in adults treated for different malignancies, but it can be equally effective in children. The activity of amifostine protects firstly from cisplatin-related nephrotoxicity and neurotoxicity, cardiotoxicity due to Dox treatment and myelotoxicity secondary to alkylating agents and carboplatin therapy. Amifostine use in supportive care for neoplastic diseases in children decreases the number of infectious complications, which can be connected to the withdrawal of the myelotoxic effect of cytotoxic agents and shortens the time of hospitalization. Liu et al. (65) have compared the roles of dihydropyridine calcium antagonists: nifedipine, nitrendipine, and amlodipine in Dox-induced nephrotoxicity in ratsm using biochemical, histopathological, and immunohistochemical approaches. Significant changes in the levels of urinary protein, serum creatinine, and BUN were found in Dox treated rats. The simultaneous application of amlodipine and Dox successfully reversed the influence of Dox on these parameters. On the other hand, nifedipine and nitrendipine exerted neither positive nor negative influences on Dox-induced changes in the levels of all three measured parameters. Moreover, in rats treated with Dox, the levels of MDA, NO, and NOS significantly increased, while GSH, GST, and SOD were decreased. Biochemical and histopathological examination showed that Dox caused significant structural damage in the kidneys, as well as pathological varies in Bcl-2 and Bax expression. The presented results clearly indicate that amlodipine protected against Dox-induced nephrotoxicity, while nifedipine and nitrendipine had no effect (65).
Dexrazoxane (Dex) has been licensed in Europe and the US for the prevention of anthracycline extravasation injury. It should be given once daily for three consecutive days. The suggested dose at day one is: 1000 mg/m 2 ; at day two: 1000 mg/m 2 ; and at day three: 500 mg/m 2 . It is also prescribed that this dose should be administered as an i.v. infusion over 1-2 h into a large vein other than the one affected by the extravasation injury. Furthermore, the first infusion should be initiated as soon as possible and within the first 6 h after the accident (66). Dex is the only agent that has undergone a clinical trial for protective use against Dox-induced cardiotoxicity. Additionally, Dex treatment is well tolerated and offers ease of use. Given the high degree of the efficacy of Dex, it is likely that Dex will become, and will remain, the exclusive standard treatment for Dox-induced extravasation injury for some time to come. Recently, Elbl et al. (80) confirmed the protective influence of Dex on late anthracycline cardiotoxicity in pediatric patients. They examined 108 patients treated with Dox or daunorubicin for a malignant disease and the results showed that Dex reduces the risk of late clinical and subclinical cardiotoxicity and does not change the response rates to chemotherapy and overall survival during the median follow-up period of 7 years (80).
Doxycycline protection against Dox-induced oxidative stress and apoptosis in mouse testes was observed by Yeh et al. (71) . The precise mechanism of Dox testicular toxicity is still not completely known, but the lessons learned from Dox cardiotoxicity imply that breakage of DNA continuity, overload of oxidative stress, and apoptosis of cells should be largely attributable. Male mice at 5-weeks of age were treated with Dox alone (3 mg/kg, i.p. every other day for 3 doses), doxycycline alone (2.5 mg/kg, i.p. every other day for 3 doses), or Dox plus doxycycline (each dose given 1 day post-doxycycline). Four weeks later, only the mice treated with Dox showed smaller body and testicular weight, reduced sperm count, impaired spermatogenetic capability, increased oxidative stress (MDA), decreased anti-oxidant activity (SOD, and GSH-Px), and elevated apoptotic indexes (upregulation of Bax and Bad; downregulation of Bcl-2 and Bcl-xL; release of cytochrome C from mitochondria to cytosol, activation of caspase-3, and increase of cleaved caspase-3 abundance and TUNEL posi-tive cells). On the other hand, doxycycline pretreatment could effectively prevent nearly all of these abnormalities (71).
There are no adequate and well-controlled studies on the use of doxycycline in pregnant women or even on the influence on spermatogenesis in healthy men, but some scientific papers and evidence confirmed a potential teratogenic risk of doxycycline usage. It is also very important to point out its side effects, which could play the most important role in deciding why not to use doxycycline as a protective agent for Dox-induced testicular toxicity. Doxycycline is a licensed drug, and accordingly, clinical trials for patients with some of the malignancies treated by Dox are strongly recommended, otherwise it cannot be suggested for a protective role. One of the questionable investigations is the potential use of morphine against Dox-induced cardiotoxicity. Kelishomi and co-workers (72) presented a positive influence of morphine on Dox-induced toxicity in male Sprague-Dawley rats. The rats were treated with Dox (1.25 mg/kg, i.p.) and/or morphine (10 mg/kg, i.p.), 4 times per week, for 28 days. The electrocardiographic parameters and the contractile force of the left ventricular papillary muscle, as well as macro-and microscopic changes were evaluated. Despite the considerable and confirmable results of morphine's protection against a high dose of Dox, given as a multiple, low, unitary dose regimen, our opinion is very similar to that expressed for doxycycline. According to the known effects of morphine and its narcotic influence, clinical trials are strongly recommended to prove its cytoprotective influence in Dox-induced toxicity and its benefits in comparison to other approaches or licensed drugs, such as Dex.
A combination therapy with Dox and docetaxel is much more effective against metastatic breast cancer than previously used therapies, due to the differences between the mechanisms of action employed by Dox and docetaxel. A preclinical study on mice made by Sakaguchi et al. (77) showed that pre-administration of docetaxel protects against Dox-induced cardiotoxicity. When the dose of Dox was changed from 2.5 to 15 mg/kg, the survival rate was higher in all the doceraxel-Dox groups, compared with the Dox-alone groups. At the same time, when the dose of doceraxel was changed in the range of 3.125 to 12.5 mg/kg, it caused a dose-dependent reduction in toxic death. According to all results presented in the investigation of Dox and doceraxel, it was proven that pre-treatment of doceraxel may protect against Dox-induced toxic death and cardiotoxicity.
The prominent cardioprotective effects of the third-generation beta-blocker nebivolol against anthracycline-induced cardiotoxicity, using the model of an isolated perfused rat heart, were examined by de Nigris et al. (78) . Sprague-Dawley rats were treated with Dox and daunorubicin in combination with nebivolol or carvedilol. The co-treatment of beta-blockers and anthracyclines had reduced the release of GSSG and GSH. A more significant reduction was shown with nebivolol than with carvedilol. Also, significant reductions of CK and troponin T activities were observed when the hearts were treated with nebivolol. At the same time, GSH-Px, MnSOD, and nitrite/nitrate release were increased after the co-treatment. Three cardiac parameters have been used to evaluate the cardiac toxicity of both anthracyclines and beta-blocker-anthracycline combinations. The left ventricular pressure developed under a constant perfusion pressure (LVDP), then the variation rates of this parameter were observed during contractility (LV/dt) max and relaxation (LV(dP/ dt) min . Nebivolol in combination with anthracyclines had exerted the most significant protection of heart tissue.
For about two decades, the use of erythropoietin has been focused on its direct effect on hematopoiesis and correction of anemia. It has been shown that erythropoietin might exert a beneficial effect on the cultured cardiomyocytes in vitro.
Recently published in vivo studies suggest that clinically available cytokine may play a protective role against nonhematopoietic diseases, including cardiotoxicity induced by Dox, infarction and ischemia-reperfusion injury in the heart (67, 74, 79) . In vivo-in vitro investigations on isolated neonatal Wistar rat cardiomyocytes and Wistar rats, respectively, were done by Chen et al. (79) . Erythropoietin showed significant changes in ameliorating Dox-induced apoptosis of cultured cardiomyocytes as established by the TUNEL assay. According to the in vivo results of rats, cardiac function extensively decreased in the Dox group. On the other hand, the combination of Dox and erythropoietin showed a considerable improvement in cardiac function, inhibition of cardyomyocyte apoptosis, a reduction of fibrosis, as well as up-regulation of Bcl-2 protein expression.
The CB 1 antagonist rimonabant is emerging as a novel therapeutic agent for obesity and related cardiometabolic risk factors in humans. Mukhopadhyay et al. (81) explored the effects of two CB 1 antagonists, rimonabant and AM281, on Dox-induced cardiac dysfunction and cardiotoxicity in vivo and in vitro. Hemodynamic measurements in mice, as well as western immunoblot analyses, a cell viability assay, flow cytometry, and endocannabinoid levels were investigated. The observed protective effect of CB 1 antagonists and the Dox-induced increase in myocardial anandamide content may, therefore, suggest that Dox-induced cardiotoxicity is associated with and mediated, at least in part, by the activation of the endocannabinoid system. The presented results (81) suggested that the CB 1 antagonist may represent a new cardioprotective strategy against Dox-induced cardiotoxicity and perhaps other cardiovascular pathologies associated with increased cell death.
According to all presented and recently published results for drugs acting as potential protectors in Dox-induced toxicity, we have to conclude that clinical trials and further studies are warranted to investigate and compare the individual mechanisms of beneficial effects.
New Antioxidants
Fullerenes are a type of carbon molecule first discovered in the mid-1980s. The most well-known of these is the buckyball, which is a closed spherical molecule, shaped like a soccer ball. The fullerenes discovered by Peter Harris and colleagues were completely closed and comparatively large, containing around 6,000 to 10,000 carbon atoms each, and with a generally disordered structure. Since the Allende meteorite has been shown to have formed at the same time as our solar system's planets, the results, which show fullerenes are capable of surviving for billions of years in space, present a further step towards accepting where life came from. The findings also support previous claims by astrobiologist Luann Becker at the University of Washington in Seattle, that fullerenes were present in carbonaceous material from meteorites (83). Many aggressive studies are presently ongoing to search for pharmaceutical products that can capitalize on the outstanding bioactivity of fullerenes and their derivatives. Up to now, different fullerene properties have been put to use, such as its ability to eliminate radicals as well as its particular molecular structure. Studies have found it to be efficient in the suppression of metastases, the treatment of cerebral conditions such as Alzheimer's and Parkinson's diseases, HIV treatment, and type-C hepatitis therapy. Recently, a drug-developing venture business has succeeded in licensing a potential fullerene drug for the treatment of cerebral conditions to a major pharmaceutical company (84).
A polyhydroxilated derivative of fullerene, named fullerenols C 60 (OH) n is being extensively studied due to its great potential as an antioxidant. It is proposed that fullerenols may act as a free radical scavenger in biological systems, in xenobiotics, as well as radioactive irradiation-induced oxidative stress. It has repeatedly demonstrated protective effects against cytotoxicity of Dox in animal models (Table III) , especially by fullerenol C 60 (OH) 24 (56-61).
Sprague Dawley outbred rats with chemically induced mammary carcinomas were used to investigate a potential protective role of fullerenol against cardio-, hepato-, nephro-, and pulmotoxicity induced by Dox (56-59). According to preliminary studies on healthy adult Wistar rats (60, 61) Djordjevic-Milic et al. confirmed that 100 mg/kg (i.p.) of fullerenol administered 30 min before Dox have a protective influence on heart and liver tissue. Therefore, that dose was chosen as effective against acute Dox-induced toxicity in further examinations (56-59).
Dox caused nephrotoxicity, but pre-treatment with fullerenol prevented oxidative stress, lipid peroxidation, and a disbalance of GSH/GSSG level in kidney tissue caused by Dox. Recent results confirm the satisfactory nephroprotective efficacy of fullerenol in the acute phase of toxicity and encourage further studies of it as a potential nephroprotector (58). An in vivo-in vitro study was examined to confirm the potential protective role of fullerenol C 60 (OH) 24 on Dox-induced liver toxicity, using female Sprague-Dawley rats and human hepatocellular carcinoma-HepG2 (56). The results showed that treatment with Dox alone caused significant changes in the serum levels of ALT, AST, LDH, and α-HBDH, as well as in the levels of MDA, GSH, GSH-Px, TAS, GR, CAT, and SOD in the liver tissue. These effects were radically reduced for all investigated parameters by pre-treatment with fuller-enol, although not for the MDA and GSH level. The HepG2 cell line was continuously treated with fullerenol for 12, 24, 48, and 96 h, at concentrations of 10 and 44 μg/mL. With the aim of evaluating the modulating activity of fullerenol on Dox-induced hepatotoxicity, the cell line was concurrently treated with Dox (1 μM; 5 μM) and fullerenol (10 μg/mL; 44 μg/mL) in different combinations. When the cells are treated with 5 μM Dox along with the fullerenol, a significant development of cell capability during the entire timeline can be seen. It was concluded that fullerenol has cytotoxic effects on HepG2 by itself, but when the oxidative stress is too high, the cytotoxic effects of fullerenol are overcome by its protective role as a strong antioxidant compound (56).
Damage to the heart muscle after Dox administration was also confirmed by changes in the ultra-structural pathology results and SOD, MDA, CAT, GSSG, GR, and TAS levels, as was a potential cardioprotective influence of fullerenol as a pretreatment agent for Dox therapy in the acute phase. Fullerenol itself, in a dose of 100 mg/kg, did not affect heart injury in rats with breast cancer. The presented results suggested that fullerenol might be a potential cardioprotector in Dox-treated individuals, but only after an improvement of the desired physical properties of fullerenol, especially the ones concerning solubility of the solid-state form in water (57).
The key benefit of fullerenol, in contrast to other known antioxidants or cytoprotectors, is its dual function as radio-protector and organo-protector (heart, liver, kidney, and lung) during the anticancer therapy (radio-and chemo-) (56-61, 85, 86). However, before a conclusive statement may be made about the potential usefulness of fullerenol as an adjunct to Dox therapy, there is a need to undertake further studies, including a chronic investigation in animals and human trials.
Other Approaches
Historically, the treatment of tumors has used surgery, radiation treatment and/or chemotherapy. Each of these has improved dramatically over the past decades. It is critical for the patient to get the correct treatment for cancer the first time. This is because the treatment of relapsed cancer isn't as successful as a proper initial treatment, when the diagnosis is first made. On the other hand, newer techniques of pinpoint-accuracy radiation, microsurgery, chemotherapy, and gene therapy offer more hope for the patient with different types of cancer than ever before. Medical professionals use the term "compassionate use" to refer to the treatment of a critically ill patient using a new, unapproved drug when no other treatments are obtainable. Drugs that are being precisely tested, but have not yet been approved by the United States Food and Drug Administration, are called investigational drugs. All known approaches are very difficult for the patient, and nowadays scientists are not only looking for new antineoplastic agents, but also for new kinds of prevention and treatment in the early stage of illness.
Exercise training has been shown to present protection against a variety of acute and chronic myocardical insults, particularly ischemia and reperfusion (I/R). It has been frequently shown to evoke increases in myocardial supeoxide dismutase and heart shock protein-72 (Hsp72). These have been proposed as mediators of cardioprotection, by providing resistance against the superoxide radical and preserving protein purpose during states of cellular stress, respectively. Without a doubt, animals with elevated myocardial levels of SOD or Hsp72 have demonstrated cardioprotection against I/R and Dox treatment. However, exercise-induced cardioprotection (EIC) has been observed in the absence of any increase in SOD or Hsp72, indicating that other protective mechanisms must be involved (87, 88). Chicco et al. (87, 88) in their two recently published papers investigated the impact of exercise training on Dox-induced toxicity according to changes in animal characteristics, such as MnSOD, CuZnSOD, MDA, and GSH-Px activity as well as Hsp72 protein content, caspase-3 activity, and myosin heavy chain isoform distribution in the left ventricular homogenates. The investigation of the influence of chronic exercise training on heart function during Dox treatment was carried out on rats, which were exercise trained for 12 weeks. Then, 15 mg/kg (i.p.) of Dox was administrated. 5 days after treatment the animals were sacrificed. The hearts were isolated and Langendorf-perfused to test cardiac function and biochemical markers. Significant inotropic, lusitropic, and chronotropic cardiac dysfunction, reduced coronary flow, and increased cardiac lipid peroxidation was found in the sedentary animals after the application of Dox. It was also confirmed that Dox had an influence on decreasing cardiac MnSOD and increasing Hsp72, as compared with the saline control group. The results of that investigation established that chronic exercise training before Dox treatment protects against cardiac dysfunction following treatment, and presented facts for a continued increase in myocardial Hsp72 following exercise training and Dox treatment in vivo (87). Furthermore, Chicco et al. (88) used one more approach to confirm the potential protective influence of low-intensity exercise training, not before, but during Dox treatment Male Sprague-Dawley rats either remained sedentary or were exercise-trained on a motorized treadmill (15 m/min, 20 min/day, 5 days/week) for two weeks. During the same period, Dox (2.5 mg/kg, i.p.) or saline was administered to sedentary and exercised rats 3 days/week, 1-2 h following the exercise training sessions (cumulative Dox dose of 15 mg/kg). Five days after the final injections, the hearts were isolated and the findings suggest that low-intensity exercise training applied during chronic Dox treatment protects against cardiac dysfunction following treatment, possibly by enhancing antioxidant defenses and inhibiting apoptosis (88).
Those two approaches are very interesting and represent a non-radical way of heart prevention against the toxic influence of Dox, but we still mustn't forget that patients get chemotherapy almost always after some surgerical intervention. On the other hand, the condition of the body is also very important and as is the stage of cancer growth and potential metastasis. Therefore, we think that those results are not useful for the in vivo applications of the new approaches, or some further in vivo studies with rats or even people who have different stages of cancer, have to be conducted. Mitra et al. (89) identified molecular mechanisms that are responsible for the protective effects of diet restriction against Dox-induced acute cardiotoxicity. Male Sprague-Dawley rats were maintained on a restricted diet, which means 35% less food than ad libitum. Cardiotoxicity was approximated by measuring the biomarkers of heart failure, lipid peroxidation, cardiac function, and histopathology. Dox was administered in a dose of 12 mg/kg by an i.p. route. Mechanistic tests showed that diet-restricted rats were protected as a result of lower oxyradical stress from increased cardiac antioxidants leading to down-regulation of separation proteins 2 and 3, and the initiation of cardiac peroxisome proliferators activated receptor-α, while plasma adiponectin increased cardiac fatty acid oxidation and mitochondrial AMPα2 protein kinase. In addition, a higher cardiac ATP/ADP ration, ATP, and erythropoietin levels were found and confirmed in diet-restricted rats, as well as a decreased suppressor of cytokine signaling 3, which up regulates the cardioprotective JAK/STAT3 pathway. These presented results suggest that diet restriction may be able to moderate the carditoxic effects of Dox by suitable pharmacological receptor and transcriptomic interventions (89). Of course, this approach also has to be confirmed with results on humans and all physical conditions, including the influence of BMI level, have to be taken into consideration.
New Drug-delivery Systems and Doxorubicin Application
A promising approach to increasing the efficacy and lowering the side effects of Dox is its binding to drug-delivery systems such as nanoparticles, liposomes, and different cancertargeting systems. All these approaches are very important and useful for new formulations of anticancer drugs. The technology is very complex and expensive, but lower toxicity, as a result of modulated carrier systems with very fine powders and specific compounds for targeting cancer, is part of modern pharmacotherapy. For therapeutic applications as drug carriers, the liposomes can be injected intravenously, and when they are modified with lipids, which make their surface more hydrophilic, their circulation time in the bloodstream can be increased extensively. Such so called "stealth" liposomes are mainly being used as carriers for hydrophilic anticancer drugs like Dox. To additionally increase the spe-cific binding properties of a drug-carrying liposome to a target cell, such as a tumor cell, specific molecules (antibodies, proteins, peptides) are attached to its shell. The size of these spheres is very small, on the order of a nanometer. Accordingly, sometimes there is no difference between nanoparticles and nano-liposomal systems. If we are talking about nano-liposomes with cancer targeting abilities, all mentioned approaches at the beginning of this paragraph can be viewed as just one new drug-delivery system. Therefore, we will try to review the recently presented innovations and critically evaluate their advantages and disadvantages.
Nanoparticles and Doxorubicin
Cancer-connected examples of nanooncology take account of injectible drug-delivery nanovectors, such as liposomes for the therapy of cancer, biologically targeted, nanosized magnetic resonance imaging contrast agents for intraoperative imaging in the context of neurooncological interventions, and novel, nanoparticle-based methods for high-specificity detection of DNA and protein (9). Nanotechnology allows the selection of the appropriate combination of agents, targeting these agents at the early stage of cancer lesions to eliminate or contain them without collateral effects on healthy tissue. Modern and recently published approaches of using nanotechnology in Dox therapy are presented in Table IV (90) (91) (92) (93) (94) (95) (96) (97) (98) (99) . Dobson (90) has recently reviewed the topic of magnetic nanoparticles for drug-delivery. In these systems, the drug is attached to a biocompatible magnetic nanocarrier and magnetic fields generated outside the body are focused on specific targets in vivo. There are several potential approaches for the synthesis of magnetic nanocarriers for drug-delivery systems. Particles may be produced that have a core-shell structure. Usually, the core is a magnetic iron oxide (magnetite or maghemite) and the shell is commonly a polymer such as dextran, silica, or PVA. Also some metals, such as gold, can be used for shell formation by attaching functional groups via cross-linkers. Recently, gold/cobalt nanoparticles with a core-shell structure and a tailorable morphology have been synthesized in the range of 5-25 nm. In order to keep the magnetic nanoparticle-drug complex at a particular location, the externally applied field must have quite a strong gradient for the treatment to succeed.
Since the work of Widder and others, three decades ago, other groups have developed and advanced magnetic microand nanoparticle-based drug-and gene-delivery systems with changeable results. The method has been very successful in several animal studies, including the first study by Widder, in which Dox was coupled to magnetic particles and targeted at sarcoma tumors implanted in rat tails. Total reduction was achieved in the magnetic-targeting group while there was no proof of decrease in the control group, which was administered 10 times the dosage, but without magnetic targeting (90).
A more recent study was carried out on four patients using technology developed by the FeRx Corporation. This investigation was intended to evaluate the possibility for magnetic nanoparticle-based targeting of hepatocellular carcinomas. The magnetic carrier was bound to Dox and targeted at the liver via transcatheter delivery through the hepatic artery under concurrent MR imaging. The study established that the final fraction of treated tumor volume ranged from 0.64 to 0.91, whereas the fraction of affected normal liver volume ranged from 0.07 to 0.30. This result provides a suggestion that the coupling of MR imaging/angiography could be used in some cases to optimize magnetic targeting (90).
On the other hand, in contrast to magnetic nanoparticles, most of the experiments are based on chemically-induced and formulated nanocarrier, into which drugs are incorporated (92, 93, 96, 99) . A toxicological study, cardio-and testicular toxicity of Dox bound to poly(butyl cyanoacrylate) or human serum albumin nanoparticles coated with polysorbate 80, was performed in healthy rats by Pereveryeva et al. (92) . Adult male Wistar rats received 1.5 mg/kg/day of Dox-loaded-poly(butyl cyanoacrylate) or human serum albumin nanoparticles calculated on Dox for three days. Body weight was estimated on days 15 and 30, and an electrocardiographic examination was performed. Clinical blood tests were performed on days 3, 5, 7, 14, and 30 in the posttreatment course. After necropsy, the organs were examined macroscopically and a histological estimation was performed for the heart and testes. The results confirmed that the hematological, cardiac, and testicular toxicity of Dox can be reduced by binding the drug to nanocarriers, such as poly(butyl cyanoacrylate) or human serum albumin. Coating poly(butyl cyanoacrylate) with polysorbate 80 added to the decrease of toxicity. The lower toxicity of the nanoformulation of Dox is possibly explained by the changed biodistribution of the drug, mediated by the nanoparticles. Azarmi et al. (93) investigated the influence of Dox-loaded nanoparticles, incorporated as a colloidal drug-delivery system into inhalable carrier particles on H460 and A549 lung cancer cells. A spray-freeze-drying technique was used and the carrier particle size was 10 ± 4 μm, while the Dox-loaded nanoparticles had a particle size of 173 ± 43 nm. A549 cells showed less sensitivity to treatment with free Dox in comparison to the H460 cell line. On the other hand, both cell lines had been highly sensitive after treatment with Dox-nanoparticles in the highest tested concentration, compared to the blank nanoparticles and the Dox-free formulation. Accordingly, the results support advancement in lung cancer treatment using Dox-loaded nanoparticles in dry powder aerosol form.
The in vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of Dox in a murine solid tumor model was recently performed by Wong et al. (96) . Dox-PLNs were prepared by dispersing Dox in tristearin and stearic acid. Subsequently, a novel anionic polymer HPSEO (hydrolyzed polymer of epoxidized soybean oil) was added to improve the drug's inclusion into the lipids. Dox-PLN, blank PLN or surfactant formulations were administered intratumorally when the tumors reached approximately 0.3 g after chemical induction of solid tumors. Tumor growth delay was measured as a value of the in vivo efficacy of treatment. It was defined as the delay in time it took for the tumor to grow to 1.13 g relative to the healthy control group of Balb/c mice. The histology and morphology of the tumor and heart tissues were examined to confirm the level of drug toxicity. According to all measured and followed parameters, the results demonstrated that Dox-PLN had significant toxic in vivo activity against solid tumors with minimal systematic toxicity.
Novel micelle-forming poly(ethylene oxide)-block-poly(εcaprolactone) (PEO-b-PCL) block copolymers, bearing a Dox side group (PEO-b-P(CL-Dox)) on the PCL block, were synthesized and tested in vitro on B16F10 murine melanoma cells. The in vitro cytotoxicity of chemically conjugated Dox as part of PEO-b-P(CL-Dox) and physically encapsulated Dox in PEO-b-PBCL against B16F10 murine melanoma cells, was assessed and compared to that of free Dox. The cytotoxicity results of micellar PEO-b-P(CL-Dox) conjugate (IC 50 of 3.65 μg/mL) were lower those that of free and physically encapsulated Dox (IC 50 of 0.09 and 3.07 μg/mL, respectively) after 24 h of incubation. After two days of incubation, the cytotoxicity of conjugated Dox (IC 50 of 0.50 μg/ mL) was still lower than the cytotoxicity of free Dox (IC 50 of 0.03 μg/mL), but surpassed that of physically encapsulated Dox (IC 50 of 1.54 μg/mL). The results point to a prospective role for PEO-b-P(CL-Dox) and PEO-b-PBCL as novel polymeric micellar drug conjugates and nano-containers, bearing hydrolyzable cores for Dox delivery.
The most important advantages of using nanooncology in modern treatment is that nanoparticles have magnetic, optical, or structural properties that are not available in larger molecules or bulk solids. Nanoparticles liganted with tumortargeting ligands, such as MAbs, peptides, and small molecules, can be used to target tumor antigens as well as tumor vasculatures with high affinity and specificity. Particles in the size range of up to 100 nm diameter have large surface areas and functional groups for conjugating to multiple diagnostic and therapeutic antineoplastic agents (100). Nanooncology and target therapy represent human-friendly health care for cancer patients, with less side effects, but their applicability is not always useful and acceptable. Therefore, for some types of cancers, we strongly recommend nanobiotechnology, but for more aggressive and non-localised cancer cells, we still have to use the old therapeutic protocols, and some other approach to cytoprotection against antineoplastic agents, such as Dox, has to be chosen.
Liposomal Doxorubicin
At present, Dox is the only liposomally formulated cytotoxic to have been licensed in the UK and it exists in a pegylated liposomal and a liposomal version. By encapsulating the drug in liposomes, anthracyclines have a longer half-life and may preferentially accumulate in tumor tissue rather than cardiac tissue, thereby providing selectivity. Pegylated liposomal Dox causes less heart failure than free Dox. The median dose producing toxicity is higher for liposomal Dox (785 mg/m 2 ) as compared to conventional Dox (570 mg/m 2 ). Liposomal Dox (Doxil™, Caelyx™) shows that it provides comparable antineoplastic efficiency against breast cancer as compared to regular Dox. Liposomal Dox preparations have less standard side effects (nausea, vomiting, alopecia, diarrhea) than Dox, but have a drastically increased risk of palmar-plantar erythrodysesthesia (hand-foot syndrome) and mucositis (1, 17, 18) . Four skin toxicities have been reported with liposomal Dox: hand-foot syndrome (40%), diffuse follicular rash (10%), intertrigo-like eruption (8%), and formation of new melanotic macules (5%). Pegylated Dox may have less toxicity than Dox, tolerating greater cumulative drug doses (1, 17) . A hypersensitivity reaction is obvious within moments of starting the infusion of liposomal Dox (10% of patients) and may include blood pressure changes (hypotension or hypertension), breathlessness, severe anxiety, flushing, a diffuse erythema, angioedema, itching, and chest pain (1). There are a lot of recently published papers on liposomal Dox (Table IV) , and some of the investigations (101-111) we will describe with more attention according to its successfully and interesting.
Polymer inclusion on liposomal membranes has been comprehensively considered as a method of enhancing the circulation time of liposomes in the bloodstream. Han et al. (103) investigated the in vitro and in vivo properties of liposomes whose surface was modified using a comb-like polymer comprised of a poly(methyl methacrylate) (PMMA) backbone and short poly(ethylene oxide) (PEO) side chains. Circulation time, biodistribution, and the antitumor activity of Dox-loaded liposomes incorporating the comb-like polymer were estimated in the B16F10 melanoma tumorbearing mice. The circulation half-life time of the comblike polymer-incorporated liposomes in the bloodstream was approximately 14-or 2-fold higher than that of the usual or polyethyleneglycol liposomes (PEG-liposomes), respectively. Moreover, in the biodistribution assay, the increase of the investigated liposomes inside the tumor was higher than that of the other liposomes. Accordingly, the antitumor activities of the comb-like polymer-incorporating liposomes were higher than those of conventional liposome formulation of Dox or free Dox, due to the higher passive tumor-targeting efficiency of the long-circulating comb-like polymer-incorporating liposomes.
PEGylated liposomes are well-known and well investigated systems in the new Dox drug-delivery systems. Recently, two research groups (104, 108) investigated the effect of Dox-encapsulation, a high-dose first injection, and the connection between AUC and the toxicity/efficacy of different PEGylated liposomes. Reasonably designed liposomes could advance the therapeutic indexes of chemotherapeutic drugs, due to alterations in the pharmacokinetics and biodistribution of encapsulated drugs. The accumulation of drugs in neoplastic and healthy tissues could be connected with efficacy and toxicity. For the purpose of investigating the connection between the AUC value of a liposomal drug and its efficacy and toxicity, Cui et al. (104) designed two pegylated liposomal Dox formulations (PLD-75 and PLD-100), which had the same lipid/drug ratio and the same bilayer composition, but different sizes and different internal ammonium sulphate concentrations. A faster release rate of PLD-75 (small size formulation) was established according to in vitro drug-retention tests. The plasma pharmacokinetics of PLD-75 were similar to that of PLD-100, in spite of whether the mice were tumor-free or not, despite the fact that, in the tumor-bearing mice, the plasma Dox level in the PLD-75 group was only about 59% of that in the PLD-100 group at 48 h post-injection. Additionally, their biodistribution behavior in S-180 tumor-bearing KM mice was extensively dissimilar. Compared with the animals receiving PLD-100, those receiving PLD-75 had a confirmed, approximately 23% decreases of liver, spleen, and lung AUC. The tumor AUC ratio of PLD-100/PLD-75 after its administration was 1.7. The highest drug levels achieved in the tumors were 33.80 μg/g (for PLD-100), and 20.85 μg/g (for PLD-75). On the other hand, improved drug accumulation does not indicate increased antineoplastic effect, and at the same Dox dose level, PLD-75 was more effective. In contrast, PLD-75 caused a more rapid and severe body weight loss, while the drug accumulation in healthy tissues was reduced. The presented facts show that liposomal systems are more difficult than conventional drug delivery systems, and it is hard to predict the efficacy and toxicity of liposomal drugs on the basis of liposomal drug accumulation.
The antitumor activity of heparin-stabilized Dox-loaded liposomes was also recently investigated in vivo by . The goal of their study was to examine the effect that heparin conjugation to the surface of Dox-loaded liposomes would have on circulation time, biodistribution, and antitumor activity after an intravenous injection given to murine B16F10 melanoma tumor-bearing mice. The stability of the heparin-liposomes in serum was higher than that of the control liposomes. It was attributed to the heparinliposomes being better protected from the adsorption of serum proteins. High drug levels were observed for up to 64 h after the intravenous injection of the Dox-loaded heparinliposomes. Additionally, the half-life of Dox was higher than that of the control liposomes or polyethyleneglycolfixed liposomes (PEG-liposomes). The heparin-liposomes accumulated in the tumor to a greater extent than the control or PEG-liposomes, which resulted in their lower uptake by the reticuloendothelial system cells in the liver and spleen. In addition, the Dox-loaded heparin-liposomes retarded the growth of the tumor successfully, as evaluated by the control or PEG-liposomes according to in vivo results in mice.
As we can see from the previously presented and reviewed studies, PEG liposomes are very successful and popular in modern cancer pharmacotherapy. The problem is that their efficacy and toxicity in different systems depends on the dose and the type of neoplastic tissue. Immuno-liposomes are powerful carriers, used for targeting therapeutic drugs at specific cells. The membrane type-1 matrix metalloproteinase (MT1-MMP) is expressed on angiogenic endothelium cells as well as on tumor cells. Subsequently, the MT1-MMP might be useful as a target molecule for tumors and neovascularity. Hatakeyama et al. (107) presented the usefulness of antibodies against MT1-MMP as a targeting ligand for a liposomal antineoplastic drug. Fabʹ fragments of an antibody against MT1-MMP were adapted at the distal end of the polyethylene glycol of Dox-encapsulating liposomes, Dox-sterically stabilized immunoliposomes (Dox-SIL[anti-MT1-MMP(Fabʹ)]). The adjustment with the antibody considerably improved cellular uptake of Dox-SIL[anti-MT1-MMP(Fabʹ)] into the HT1080 cells, which highly express MT1-MMP, as compared to the non-targeted liposomes [Dox-stealth liposomes (Dox-SL)]. It suggests that the MT1-MMP antibody (Fabʹ) is an effective targeting ligand for MT1-MMP expressing cells. A significant suppression of tumor growth, as compared to Dox-SL, was shown in vivo by the systemic administration of Dox-SIL[anti-MT1-MMP(Fabʹ)] into the tumor-bearing mice. On the other hand, tumor accumulations of both investigated liposomes were similar; suggesting that those liposomal formulations accumulated in the tumor via an enhanced infiltration and retention effect, but not via the targeting of the MT1-MMP expressed on both the endothelial and the tumor cells. Therefore, the improved antitumor activity of Dox-SIL[anti-MT1-MMP(Fabʹ)] resulted from an acceleration of the cellular uptake of liposomes, due to the included antibody after extravasation from the capillaries in the tumor.
A lot of pre-clinical studies in the last decade have investigated Dox-liposomes and results differ from case to case. PE-Gylated liposomal Dox as a very popular new drug-delivery system is also being tested in the treatment of patients with advanced classic Kaposi sarcoma (111). The patients were treated with PEG-Dox liposomes every 3 weeks in anticipation of disease progression or the occurrence of intolerable side effects. Objective responses were determined after 3 and 6 cycles, while the toxicity was assessed every cycle. Twenty men with pretreated classic Kaposi sarcoma received 20 mg/m 2 of PEG-Dox liposomes. Total and limited responses were observed in 10% and 70% of investigated patients, respectively. Neutropenia was the most considerable grade 3 hematologic toxicity, observed occurring in 20% of patients. Only one patient (5%) demonstrated grade 4 neutropenia. 70% of patients achieved a remission of pain and/or edema after 6 cycles. It was confirmed that PEG-Dox liposomes are connected with an improvement in objective reaction and pain intensity and are well tolerated as a second-line treatment for classic Kaposi sarcoma.
PEGylted liposomes are very popular in modern drug-delivery systems for targeted therapy. PEGylated liposomes encapsulating Dox (Doxil™) are currently used in clinical settings. Targeting liposomes with an indifferent structure and a specific drug at specific cells is a promising approach for reducing side effects and improving therapeutic effects.
Targeting Cancer and Doxorubicin -Other Approaches
The modern focus of advancement in neoplastic therapies is on targeted drug delivery to deliver therapeutic concentrations of anticancer agents to the site of action and spare the healthy tissues. As was described above, nanoparticles and liposomes are the most popular formulations used in targeting cancer, but they are not the only one. In the literature data, we can also find some very interesting information about the applications of dendrimers for cancer treatment (14, 112, 113) , as well as polymeric micelles in oral chemotherapy (15), polypeptide-Dox as a prodrug (114), micellar encapsulated Dox (115-120), different conjugated forms (121-125), and the use of novel tissue adhesives with Dox (126, 127).
Polymeric micelles have important potential as drug-delivery carriers for a wide array of antineoplastic agents. Several formulations of Dox, comprising drug-loaded micelles of mixtures either of Pluronic™ PEO-b-PPO-b-PEO copolymers (SP1049C) or of PEG-b-poly(aspartic acid) (NK911), show potential for advancement into clinical trials. Most of the tumor-targeting polymeric micellar formulations for oral administration are presently in preclinical improvement. The enormous advantage of these micellar systems is that they have been purposefully designed to find their way into systemic circulation, thus incorporating either relatively short or biodegradable polymeric segments. Presently, over 50 different oral antineoplastic drugs have already been licensed in the US and Japan markets. Nevertheless, modern formulations of drugs regularly given i.v.
will allow efficient oral cytotoxics (1, 15, 16, 100) .
Recently, advances have been made in the application of biocompatible dendrimers for cancer treatment, being used as delivery systems for potent anticancer drugs such as cisplatin and Dox. Star-like carriers of the anticancer drug Dox have been prepared and investigated via the conjugation of poly[N-(2-hydroxypropyl)methacrylamide] macromonomers to PAMAM dendrimers, followed by an attachment of the drug to the polymer arms by a biodegradable peptide spacer. The compact structure of the star polymer results in slower rates of enzyme-mediated drug release, thus decreasing the cytotoxicity of the conjugate. For the same purpose, hybrid polymers conjugated to Dox via a hydrazone linkage have been examined. The hydrazone linkage is stable at a physiological pH of 7.4, but is designed to undergo hydrolysis on the uptake of the polymers by endocytosis and subsequent trafficking of the conjugate to mildly acidic subcellular organelles such as endosomes and lysosomes. These drug conjugates show an increased circulation time of more than 1 h and are toxic to a range of tumor cell lines. An evaluation of these hybrids of polyester dendrimers and PEO star polymers as anticancer drug-delivery systems is in progress (14, 112). One of the new examples of an architecturally-optimized dendritic drug-delivery system was reported using an asymmetric Dox-functionalized bow-tie dendrimer, composed of PEG and 2,2-bis(hydroxymethyl)propionic acid. A pH sensitive linkage between the drug and dendrimer was used to release the drug inside the cell. A subsequent i.v. application to Balb/c mice with s.c. C-26 colon carcinoma tumors, showed that tumor uptake was around 9-fold higher in contrast to free Dox. A complete tumor regression and a 100% survival rate of mice over two months was observed after a single injection of Dox-conjugated dendrimer, while no recoveries were observed with Dox-alone treatments (14).
In the past few years, there has been an increase of interest for experimentation with polymeric micelles as potential vehicles for antineoplastic drug delivery. Slower dissociation and enchased stabilization in aqueous surroundings are characteristic of polymer micelles with a relatively lower CMC as compared to conventional micelles of low-molecular weight surfactant. The most commonly used micelles are made of acid-grafted chitosan oligosaccharide (115), pluronic (116, 119), aginate sodium and chitosan (118). Lee et al. (117) used the physiological characteristics of tumors, such as angiogenesis, the expression of matrix metalloproteinases (MMPs) and the enhanced permeability and retention effect, and designed MMPs-specific PEGylated peptide-Dox conjugate micelles containing Dox. Two peptides, GPLGV and GPLGVRG (P5D and P7D, respectively), were used for the preparation of these conjugates. Dox was loaded into the micelles, formed by each conjugate. P5D and P7D were specifically cleaved by active MMP-2 and all conjugates had extensively better cell practicality than Dox at the same concentrations. In vivo, the animals treated with PEGylated peptide-Dox conjugate micelles showed approximately 50% of the tumor growth experienced by the controls, and Dox-loaded conjugate micelles inhibited tumor growth up to about 72% as compared to the controls, which matched the effect of Dox. Dox-loaded PEGylated peptide-Dox conjugate micelles demonstrated longer half-lives and continued to sustain higher concentrations of Dox in plasma than PE-Gylated peptide-Dox conjugate micelles alone. A cancer therapy with activity that is similar to that of the parent drug, but with reduced toxicity, can be offered by the Dox-loaded PEGylated peptide-DOX conjugate micelles.
For the purpose of reaching lower toxicity and higher efficacy, Dox was conjugated with lactose-human albumin couple molecules (121), alkylated poly(L-lysine citramide imide) (122), and N-(2-hydroxypropyl)methacrylamide (123-125). have used N-(2-hydroxypropyl)methacrylamide copolymer (HPMA) as a Dox carrier in three of their recently published papers. HPMA copolymer-Dox conjugates with pH-controlled activation, as well as immunoglobulin-modified polymer and graft HPMA copolymers for passive tumor-targeting were investigated. In all cases in vitro or in vivo results for polymer-Dox conjugates showed a significantly higher antitumor activity than Dox alone. Once again, it was confirmed that a lower dose of Dox, well packed into a specific, selective and bio-indifferent carrier, shows excellent efficacy without significant toxicity and side effects.
Kakinoki and co-workers (126, 127) used a novel tissue adhesive made of human serum albumin (HSA) and a tartaric acid derivative (TAD) in their research. In vitro and in situ investigations of the novel tissue adhesive containing Dox, demonstrated a more effective influence of the HSA-TAD-Dox complex than the Dox system without any pre-handling. With the same purpose, Bidwell et al. (128) examined the elastin-like polypeptide (ELP) for its capability to function as a macromolecular carrier for thermally-targeted delivery of Dox. The ELP-based Dox delivery vehicle (Tat-ELP-GFLG-Dox) consists of a peptide derived from the HIV-1 Tat protein, which enables its cellular uptake, ELP to permit thermal targeting, and the lysosomally degradable glycylphenylalanylleucylglycine (GFLG) spacer, as well as a cysteine residue, conjugated to a thiol-reactive Dox derivative. Cytotoxicity of Tat-ELP-GFLG-Dox in MES-SA uterine sarcoma cells was enhanced 20-fold when aggregation of ELP was induced with hyperthermia. The ELP-delivered Dox displayed a cytoplasmic distribution and induced temperature-dependent caspase activation.
Targeting cancer will have an important role in realizing the purpose of detecting transforming cell populations early by in vivo imaging or ex vivo analysis. It will also permit a suit-able combination of agents to be chosen, as well as the targeting of these agents at the early cancer injuries, to remove or control them without collateral effects on healthy tissue.
Conclusions
Modern cancer treatments like radiation and chemotherapy have become established as remarkably effective at treating many cancers, particularly in combination, but they exert re overwhelming toxic side effects. These treatments kill healthy cells as well as cancerous ones. Since the last decade of past century, scientists have been trying to generate new medical therapies that make use of their tiny size. Nanoparticles made of gold, carbon, and other materials can move through the bloodstream and through cell walls, allowing for efficient drug delivery, or acting like homing devices for research purposes. On the other hand, questions concerning the safety of nanoparticles remain largely unanswered. Nevertheless, the potential of nanoparticles for the creation of novel treatments has become a central thrust for many fields of medicine, including oncology. The goal is finding cancer-seeking molecules that are attracted to cancer cells, but leave healthy cells alone. During the recent years of investigations, some new ideas were born and a few newer carriers, such as liposomes, micelles, and adhesives, have been included in experiments. As a result of this hardworking period, the first ever developed liposomal anticancer drug, Doxil™, containing Dox, has been licensed.
Because of to the very slow integration of nanobiotechnology into cancer treatment, patients with specific tumors, who received Dox and had very serious side effects, including cardiomyopathy, could not wait for a large and long scientific revolution. Therefore, we can see a lot of different approaches to protect against Dox-induced cytotoxicity in last decade, such as using natural products with antioxidant activity, different well-known drugs, new antioxidants, and every day activities (exercising, nutrition habits, and lifestyle).
All reviewed articles are only one part of a very broad spectrum of different approaches and solutions against specific kind of toxicity induced by Dox. Very recently, some books (1, 129-136) have been published and we strongly recommend some of the described chapters, which could be a supplementary material to a few of only opened discussions in this review, such as naturally occurring anthracyclines (129), biosynthetic anthracycline variants (130), anthracycline biosynthesis (131), and especially molecular mechanisms of anthracycline activity (132), anthracycline cardiotoxicity (133), acid-sensitive prodrugs of Dox (134), Dox conjugates for selective delivery to tumors (135), and anthracyclinesformaldehyde conjugates and their targeted prodrugs (136).
There are a lot of opportunities, which now have to be strongly taken into consideration. Consequently, medical doctors have to choose which approach is most acceptable at a specific stage of Dox treatment for each patient, considering their body condition, type and the phase of cancer, as well as age, sex, lifestyle, and so on. Therapeutic monitoring in Dox treatment is the number one priority in protecting against Dox-induced toxicity.
